Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVT 101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | EVT 101 8 mg capsule |
| 2 | EXPERIMENTAL | EVT 101 15 mg capsule |
| 3 | PLACEBO_COMPARATOR | Matching placebo capsule |
| Name | Type | Description |
|---|---|---|
| EVT 101 | DRUG | 8 mg capsule, single oral dose |
| placebo | DRUG | Placebo capsule, single oral dose |
Inclusion Criteria: * Healthy Male volunteers * Body Mass Index between 19 and 29 Exclusion Criteria: * Subjects who received any prescribed medication within 5 half lives or 14 days of the first dose administration whichever is the longer * Subjects who have received any prescribed CNS medicatio...
EVT 101 is an investigational small molecule developed by Evotec SE. It is an NMDA NR2B-subtype selective antagonist that has been studied in Phase 1 clinical testing. The compound was evaluated in a completed trial involving healthy male volunteers in the United Kingdom.
EVT 101 targets the NMDA receptor, specifically the NR2B subtype. It acts as a selective antagonist at this receptor. This mechanism was studied in a Phase 1 trial titled "The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function."
EVT 101 is developed by Evotec SE, a company listed under the ticker EVO. Evotec is the sponsor of the clinical program for this investigational compound.
EVT 101 is in Phase 1 clinical development. It has not been approved by the FDA or any regulatory agency. The only recorded trial for EVT 101 is a completed Phase 1 study.
EVT 101 has been studied in one clinical trial: NCT00526968, titled "The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function." This Phase 1 trial was completed and enrolled 19 healthy male volunteers in the United Kingdom.
EVT 101 is not approved for any indication. It is an investigational drug that has been tested in healthy volunteers to study its effects on brain function. No specific disease indication has been disclosed for this compound.